The coronavirus disease 2019 (COVID-19) has caused more than 6.5 million deaths globally as of June 10, 2022. The severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) Omicron variant (B.1.1.529) has the greatest transmission rate and can cause hospitalization in vaccinated individuals. It has been the most distinct SARS-CoV-2 variant of concern to date. The existing inactivated vaccines made with the wild-type strain are less efficient to prevent disease and/or hospitalization associated with the Omicron variant, even after a booster dose. Hence, it is crucial to develop new vaccines that are effective against this variant. The objective of this study was to summarize the data on existing clinical trials for new COVID-19 vaccines formulated against Omicron variant. Clinical trials from the international clinical trials registry platforms were searched and analyzed. As of June 10, 2022, a total of 15 clinical trials are available consisting of six and nine clinical trials of inactivated and messenger RNA (mRNA)-based vaccine candidates containing the Omicron variant, respectively. Those trials are evaluating four inactivated and four mRNA-based vaccine candidates. Although Omicron-specific vaccines are highly desired, their development is challenging since the SARS-CoV-2 variant formation is still unpredictable. Although two vaccines from Pfizer and Moderna have been approved for emergency use in the US and the UK for Omicron variant, the Asian pharmaceutical companies such as CNBG (Sinopharm), Sinovac, and Shifa Pharmed also have Phase 3 clinical trials under development and almost all clinical trials are expected to be completed in 2023. These results should help guide academics and policymakers in the COVID-19 vaccine field regarding investments in updated booster doses against the SARS-CoV-2 Omicron variant.
Comunicamos la primera identificación en Ecuador del microorganismo Comamonas kerstersii, cepa aislada a partir de una muestra de líquido de la cavidad abdominal e identificada mediante la técnica de espectrometría de masas MALDITOF. Fue obtenida durante el acto quirúrgico de un paciente con el diagnóstico de una peritonitis aguda, secundaria a una apendicitis perforada. Este microorganismo es considerado un patógeno poco común. Pese a que el género al que pertenece tiene una amplia distribución geográfica, es considerado un agente oportunista. Palabras clave: Infecciones intraabdominales; apendicitis; Comamonas; espectrometría de masa por láser de matriz asistida de ionización desorción; microbiología.
In this article, we describe 6 cases of patients that presented to the emergency room with symptoms and laboratories compatible with the diagnosis of acute appendicitis. What attracts attention about these six cases are the results of the culture of the tissue, which reveals in these six patients the presence of the bacteria Comamonas kerstersii.
ResumenLa descripción del género Comamonas como agente infeccioso es inusual, existen muy pocos reportes en el mundo, los cuales son escasos en el Ecuador. La siguiente es una revisión bibliográfica acerca del microorganismo, efectuada a partir de Pubmed, Scielo y Google académico, en idiomas español e inglés de los últimos 10 años, con la finalidad de establecer una revisión breve del estado del arte acerca de este como patógeno. Se logró identificar la escasa evidencia disponible con base en estudios observacionales, líneas de investigación para el Ecuador (tanto en medicina como en microbiología), además se establece un marco referencial acerca de un género escasamente descrito y hasta cierto punto, "desconocido" en el ámbito de la salud.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.